Mid-dose losartan mitigates diabetes-induced hepatic damage by regulating iNOS, eNOS, VEGF, and NF-kappa B expressions


Oltulu F. , Buhur A., Gürel Ç. , Kuşçu G., Dağdeviren M. , Karabay Y. , ...More

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.5, pp.1582-1589, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 49 Issue: 5
  • Publication Date: 2019
  • Doi Number: 10.3906/sag-1901-15
  • Title of Journal : TURKISH JOURNAL OF MEDICAL SCIENCES
  • Page Numbers: pp.1582-1589

Abstract

Background/aim: Losartan, an antihypertensive drug, is highly preferred in patients with diabetes mellitus (DM) and hypertension because of its retarding effect on diabetic nephropathy. In this study, we investigated the potential therapeutic effect of different doses of losartan on hepatic damage in a streptozotocin (STZ, 50 mg/kg)-induced DM model in rats.